Context: Despite the major risk of regrowth of clinically nonfunctioning pituitary adenomas (CNFAs) after primary treatment, systematic data on the probability of further tumor progression and the effectiveness of management approaches are lacking.
C linically nonfunctioning pituitary adenomas (CNFAs) are pituitary tumors not associated with clinical evidence of hormonal hypersecretion. They have a prevalence of 7 to 41.34 per 100,000 people (1-4) and a standardized incidence rate of 1.02 to 2.34 per 100,000 (3) (4) (5) .
Unless incidentally detected, CNFAs usually escape early diagnosis because of the lack of clinical manifestations of hormonal hypersecretion; they are most often discovered when they are large enough to exert pressure effects on surrounding structures. Epidemiological studies suggest that at the time of detection, 67% to 90% are macroadenomas, representing the clinically relevant tumors in the group of CNFAs (1, 2, 5) . Surgery with or without adjuvant radiotherapy is the mainstay of macroadenomas treatment, particularly when they are associated with visual compromise or are in close proximity to the optic pathway. The treatment aims to improve/reverse the consequences of the pressure effects and to prevent further tumor growth. Despite advances in surgical and radiotherapy techniques, tumor control is not always achieved; thus, data from our centers, as well as from other departments, suggest 5-year regrowth rates of 15% to 66% after surgery alone (6) (7) (8) (9) and 2% to 28% after surgery followed by adjuvant radiotherapy (6, 7, 10, 11) . These observations dictate close monitoring, usually with annual imaging in the early postoperative years, with the aim of avoiding the consequences of late diagnosis of regrowth.
Management options for regrown CNFAs include further surgery, radiotherapy, a combination of these, or close monitoring. The decision is influenced by factors including adenoma size/location, patient's age, comorbidities, pituitary reserve, and available surgical and radiotherapy expertise. Despite the substantial risk of CNFA regrowth after primary treatment, series systematically analyzing the outcome of regrown CNFAs in terms of further tumor progression are lacking. As a result, we have no reliable data on the risk of further regrowth(s) or on the effectiveness of various approaches, and current decisions on the optimal management of this group of patients lack an evidence base.
To provide this important information, we performed a collaborative, retrospective cohort study at two large specialist UK referral centers involving systematic assessment of the probability of further CNFA growth, predictive factors, and outcomes of management approaches in a large series of patients diagnosed with CNFA regrowth and followed up for a prolonged period. Furthermore, we estimated the probability of multiple episodes of adenoma progression after the first regrowth, providing data on the poorly explored area of clinically aggressive CNFA behavior and resistance to treatments.
Patients and Methods

Study design and patients
This was a retrospective cohort study in two large UK specialist referral centers (Birmingham and Oxford). We reviewed the records of patients with histologically confirmed CNFA who, during follow-up, were diagnosed with regrowth of the adenoma after primary treatment (i.e., surgery with or without adjuvant radiotherapy). These records were identified from the databases of the centers, in which patients are classified according to diagnosis. Primary surgery for the CNFA occurred between January 1963 and December 2011, and the follow-up period ended in June 2016. The term primary CNFA was used to describe the CNFA at the time of the original diagnosis (i.e., before any regrowth). The study was retrospective in nature and involved no intervention beyond routine patient care. It was registered with and approved as an audit by the respective hospitals.
Adenoma regrowth was diagnosed on the basis of radiological appearance with or without associated clinical manifestations. The extent of adenoma resection was determined by imaging performed at least 3 months postoperatively. In our series of 237 regrown CNFAs, 94% had tumor residual visible on scan postoperatively and 6% did not. Subsequent management was decided by the endocrine, neurosurgical, and oncology teams. After the detection of regrowth, imaging surveillance was most often performed every 1 to 2 years. The end points were further CNFA regrowths (enlargement after treatment or further enlargement in cases managed by monitoring). The follow-up period was defined from the time of detection of a regrowth until last imaging. Demographic characteristics, treatments, immunohistochemical and imaging findings, further tumor progression(s), and their management and subsequent outcomes were recorded.
Statistical analyses
Percentages were calculated for categorical data and medians with ranges for continuous variables. The regrowth-free curves were generated by the Kaplan-Meier method. Cox regression analysis was used to assess the effect of various factors on regrowth, and hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. The number of subjects with no tumor visible at imaging after surgery was very small, and this precluded any analysis based on whether there was a visible tumor. There was no significant departure from proportional hazards assumptions for any of the variables. The level of significance was set at P , 0.05. Statistical analyses were performed by using IBM SPSS Statistics for Windows v. 22.0 (IBM Corp., Armonk, NY).
Results
Second regrowth
We identified 237 patients with a CNFA showing first regrowth after primary treatment, representing an overall 31% of the total of 765 patients who were treated (9, 10, 12) . Of the 765 patients treated, 678 (88.6%) had some tumor visible after surgery, and 32.9% of these had regrowth; 87 (11.4%) had no tumor visible after surgery, and 16.3% of these had regrowth. In 678 patients with residual tumor, the regrowth rates were 28.3% without adjuvant irradiation and 4.4% with adjuvant irradiation. The characteristics of the 237 patients are shown in Table 1 . Eight patients were diagnosed between 1977 and 1988, and the remainder were diagnosed after 1990.
During a median follow-up of 5.9 years (range, 0.4 to 37.7 years), 90 patients showed a second regrowth (median age, 64.9 years; range, 32.3 to 88.9 years; 42 men and 48 women). The 5-year rate for second CNFA regrowth was 35.3% [ Table 2 ; Fig. 1(a) ]. When analyzed by type of management for the first regrowth, this was 36.2% after second surgery alone (n = 33), 12.5% after radiotherapy alone (n = 58), 12.7% after second surgery combined with radiotherapy (n = 50), and 63.4% with simple monitoring (n = 95) [ Table 2 ; Fig. 1(b) ]. Of the patients with CNFAs managed by monitoring after the first episode of tumor progression, 34.8% eventually were offered intervention (surgery or radiotherapy or a combination) because of further enlargement.
On univariate Cox regression analysis, risk factors for a second regrowth were type of management offered for the first regrowth (type of treatment with reference category "Monitoring": HR surgery: 0.393; 95% CI: 0.205, 0.754; P = 0.005; HR radiotherapy: 0.098; 95% CI: 0.046, 0.210; P , 0.001; HR surgery and radiotherapy: 0.174; 95% CI: 0.092, 0.330; P , 0.001), sex (with reference category "Female": HR in males: 0.642; 95% CI: 0.423, 0.974; P = 0.037), and age at diagnosis of the primary CNFA (HR: 1.021; 95% CI: 1.005, 1.038; P = 0.009), whereas type of adenoma immunostaining was not (HR: 0.833; 95% CI: 0.675, 1.027; P = 0.088).
Multivariate regression using the factors that were significant on univariate analysis revealed that only the type of treatment and sex (risk lower in males) remained significant risk factors for a second regrowth (type of treatment with reference category "Monitoring": HR surgery: 0.463; 95% CI: 0.238, 0.901; P = 0.023; HR radiotherapy: 0.098; 95% CI: 0.045, 0.212; P , 0.001; HR surgery and radiotherapy: 0.182; 95% CI: 0.093, 0.353; P , 0.001; and sex with reference category "Female": HR in males: 0.565; 95% CI: 0.370, 0.863; P , 0.008).
In one of the patients with a second regrowth, the CNFA progression manifested with metastatic disease in the brain and spine (pituitary carcinoma with positive staining for gonadotrophins); this was detected 35 years after the initial operation for CNFA and 27 years after the first regrowth. It was managed with surgery and radiotherapy to the metastatic disease followed by temozolomide 4 years later because of progression. Further progress was detected 3 years later, and three cycles of lomustine were administered; however, this was discontinued because of thrombocytopenia. Two years later, the metastatic burden has remained unchanged.
Further regrowth(s)
Of the 90 patients presenting with a second episode of CNFA enlargement, two were not included in the review of further outcomes (one patient with pituitary carcinoma with positive staining for gonadotrophins and another patient with no follow-up scan who died shortly after the detection of CNFA progression). The remaining 88 patients were managed with surgery alone (n = 31), radiotherapy alone (n = 8), surgery combined with radiotherapy (n = 11), or simply monitoring (n = 38). Seven subjects had no follow-up imaging after the management of the second regrowth and were excluded from subsequent evaluations.
During a median follow-up of 4.3 years (range, 0.2 to 29.3 years), 22 had a third regrowth (median age, 66.3 years; range, 44.5 to 73.3 years; 10 males and 12 females). The third regrowth rate at 5 years was 26.4% [ Table 2 ; Fig. 2(a) ]. When analyzed according to the modality of One of these patients, who initially harbored a silent corticotroph adenoma, presented with metastatic disease in the spine 20 years after the primary surgery and 18 years after the detection of the first regrowth; she died 1 year later. During this interval, she developed three episodes of regrowths and clinically manifested Cushing disease requiring three surgical operations, two courses of radiotherapy, and Gamma Knife therapy.
Of the 22 patients with a third regrowth, 14 had further follow-up and were managed with surgery (n = 4) or with monitoring (n = 10); at a median period of 2.1 years (range, 0.8 to 13.8 years), seven had a further adenoma enlargement (all managed by monitoring).
In the whole group of patients with a first regrowth (and after excluding seven with no follow-up after the second one), the third regrowth rate was 4.4% at 5 years, 10.0% at 10 years, and 15.1% at 15 years. With univariate Cox regression analysis, the only risk factor for this was the type of management of the first regrowth (type of treatment with reference category "Monitoring": HR surgery: 0.046; 95% CI: 0.005, 0.429; P = 0.007; HR radiotherapy: 0.058; 95% CI: 0.011, 0.313; P = 0.001; HR surgery and radiotherapy: 0.062; 95% CI: 0.012, 0.309; P = 0.001), whereas sex (HR, 1.371; 95% CI: 0.590, 3.186; P = 0.454), age at primary surgery (HR, 1.021; 95% CI: 0.987, 1.056; P = 0.225), and immunostaining (HR, 1.117; 95% CI: 0.676, 1.844; P = 0.667) were not.
Discussion
This study involving a large series of nonselected consecutive patients with regrown CNFAs systematically assessed further tumor progression and management outcomes during a long follow-up period. We found 5-and 10-year second regrowth rates of 35.3% and 46.7%, respectively, indicating the need for regular, long-term monitoring. Therapeutic intervention with surgery and/or radiotherapy provided optimal outcomes; with monitoring alone, there was substantial probability for further enlargement (63.4% and 81.9% at 5 and 10 years, respectively). Management of the regrowth (i.e., active treatment or monitoring) was the major factor determining the risk of further growth(s). The probability of multiple episodes of CNFA progression was 4.4% and 10.0% at 5 and 10 years, respectively, with the rate increasing on prolonged follow-up. Of the CNFAs with regrowth after primary treatment, 0.84% had malignant transformation.
Nonfunctioning pituitary macroadenomas comprise the most common pituitary tumor requiring surgical intervention. However, a number of patients experience tumor regrowth after primary treatment; thus, previously published literature analyzing the outcomes of patients from Oxford and Birmingham, as well as data from other large centers, have shown that first adenoma regrowth relates to the extent of CNFA removal (10-year regrowth rate if no residual adenoma was 0% to 6%; this increased significantly to 42% to 53% with intrasellar remnant and to 77% to 80% with extrasellar remnant) (8, 9, 12) and to the administration of adjuvant radiotherapy, which significantly reduced adenoma progression (5-year regrowth rate, 2% to 28%) (6, 7, 10, 11) . Furthermore, in an Oxford cohort, the risk of enlargement increased with the length of follow-up, with 20% of the events detected at least 10 years after surgery (9) . Tumor behavior after the detection of the first CNFA regrowth has not been systematically determined; the relative rarity and the generally slow growth rate of CNFAs possibly explain the lack of relevant data in addition to the necessity for prolonged follow-up. In this retrospective cohort study of a Second regrowth rate for the total group within the follow-up period was 38%.
237 patients with regrown CNFAs and a median followup of 5.9 years after the detection of the first regrowth, we confirmed that tumor progression remains a considerable possibility, with a 10-year second regrowth rate of 46.7% and a third regrowth rate of 33.1%, dictating regular, lifelong monitoring. In a series of 81 regrown CNFAs (median follow-up, 3.62 years) managed by surgery with or without radiotherapy, Chang et al. (13) analyzed the outcomes of 52 patients with follow-up of more than 2 years and reported a 5-year progression rate of 8.5%. However, the small sample size and the short observation period are major drawbacks of this study. Although there is no consensus on the definition of aggressive CNFAs, this group is generally characterized by a high risk of regrowth(s) and resistance to treatments. In our study, we estimated the probability of multiple episodes of progression in CNFAs diagnosed with a first regrowth suggesting clinically aggressive behavior; this was 4.4% and 10.0% at 5 and 10 years, respectively, with the percentage increasing with further Figure 2 . Kaplan-Meier third regrowth-free survival curves for (a) total group of patients with a second regrowth and (b) patients stratified by type of treatment of the second regrowth (i.e., surgery, radiotherapy, surgery and radiotherapy, and monitoring).
follow-up, confirming the long natural history of these tumors.
The decision to intervene and the modality of treatment after detection of adenoma progression depend on many factors, including proximity to the chiasm/visual deterioration, tumor location/size, age, pituitary reserve, comorbidities, and available surgical and radiotherapy expertise. In 40.3% of our cases with a second regrowth, imaging surveillance was the management approach; repeat surgery was offered in 14%, radiotherapy in 24.6%, and surgery combined with radiotherapy in 21.2%. We found that radiotherapy (alone or in combination with surgery) offered optimal local control, with 5-and 10-year regrowth rates of 12.5% to 12.7% and 17.7% to 26.1%, respectively. With surgery alone, these were 36.2% and 47.8%, respectively, rendering irradiation an attractive option. It should be noted, however, that advances in imaging and surgical techniques have reduced the challenges and risks related to reoperation (14) , making this approach an alternative stop/gap during the period when the patient wishes to avoid radiotherapy. Invasion of the cavernous sinus is not a reason for favoring surgery, but a repeat operation may be inevitable for tumors that are very large or close to the optic pathways, requiring close monitoring and early detection of continuing growth potential. Similar findings were reached after analysis of the outcomes of second regrowths, although the small sample size in each management group remains a challenge. Studies looking specifically at the impact of radiotherapy on regrown CNFAs are lacking. The published literature includes series of patients with residual or regrown adenomas managed by various radiation modalities in tertiary radiotherapy centers, which were analyzed altogether, complicating the estimation of clear outcomes for our group of interest; nonetheless, overall optimal control rates have been reported (11, (15) (16) (17) (18) .
In view of the suggested adverse effects of radiotherapy (19) , its indications and timing are controversial; in many centers, this is deferred until detection of adenoma regrowth. Within the constraints of comparisons with historical data from previous literature in which radiotherapy was offered immediately after surgery (6, 7, 10) , our outcomes after irradiation for regrowth suggest that this approach achieves similar local control rates, allowing for deferral of its use until detection of regrowth and reducing the number of patients offered unnecessary irradiation. This approach requires close monitoring with imaging to detect regrown masses at an early stage, before their size dictates debulking surgery, and poses difficulties for the safe and effective administration of radiotherapy.
Radiographic evidence of CNFA progression does not necessarily require therapeutic intervention, and imaging surveillance is a rational approach in asymptomatic regrowths or when intervention is contraindicated. The outcome of monitoring for regrown CNFAs has not been previously assessed. We found that after detection of the first episode of enlargement, the 5-year rate of further enlargement was 63.4% (48.3% after the detection of a second regrowth), pointing to the importance of close monitoring and a timely decision to intervene when the tumor is in proximity to the chiasm or shows continued progress. Among our regrown CNFAs managed by monitoring after a first regrowth, 34.8% required intervention. Factors predicting further progression have not been identified, and data on the natural history of nonoperated, presumed CNFAs would not apply to this specific group of tumors, which already demonstrated progressive behavior despite treatment. Notably, the growth of CNFAs is characterized by different models of unknown pathophysiology (exponential, logistic with initial growth followed by deceleration) (20) , and predictive parameters are not available. In a selected retrospective series of 12 operated (and nonirradiated) CNFAs presenting with enlargement, Honegger et al. (20) found considerable variability in tumor volume-doubling time (between 1 and 27.2 years), confirming the significant variations in tumor progression; interestingly, no significant correlation between initial volume and doubling time was confirmed.
The pathophysiological mechanisms implicated in aggressive CNFA behavior have not been elucidated, and validated prognostic biomarkers are not available (21) . Established clinical predictors of CNFA regrowth after primary treatment are the extent of adenoma resection and postoperative irradiation (9, 22, 23) , whereas age, sex, initial tumor size, invasiveness, and histology have not been consistently verified as having prognostic significance (24) . In our series of CNFAs with one previous episode of progression, type of management of the regrowth was a predictor of further progress and sex was a predictor only for the second episode; the significance of the latter finding has not been elucidated. Young age at diagnosis of the primary CNFA and type of immunostaining did not predict aggressive behavior. Notably, there is controversy as to whether CNFAs with staining for adrenocorticotropic hormone (ACTH) demonstrate worse prognosis with multiple regrowths (25, 26) , and our study with 28 cases (16% of the cohort) did not support this. Previous analysis of patients in Oxford with CNFA showed that staining for ACTH was not an independent predictor of first regrowth (9) . Nonetheless, cases of silent ACTH adenomas showing aggressive behavior after the first regrowth have been reported (25) , and one of the two CNFAs in our study showing malignant transformation was a silent corticotroph adenoma.
Pituitary carcinomas account for 0.1% of pituitary tumors and require a multidisciplinary treatment approach (27) . No data have been published on the rate of regrown CNFAs demonstrating malignant transformation. In our series, malignant transformation was diagnosed in 0.8% of CNFAs diagnosed with regrowth. Although latency periods between 4 months and 18 years have been reported, in our cases the interval was extensive (21 and 35 years) . Overall, prognosis is poor, and most patients die within 1 year of diagnosis (27) . However, one of our patients had an unusual clinical course with survival of at least 9 years, highlighting the unpredictability of this condition. The development of florid Cushing syndrome and malignant transformation from a silent corticotroph adenoma, as in our second case of pituitary carcinoma, is exceptionally rare, and the biological mechanisms remain enigmatic.
The limitations of our study are its retrospective, nonrandomized nature, making it vulnerable to selection bias for the management approaches (however, a prospective randomized study may not be feasible), and the fact that a (small) number of patients lacked follow-up after detection of further enlargement (in most of them, repeat imaging had not taken place by the end of the project). The advantages are the large number of well-characterized and nonselected subjects with a rare condition from two large UK pituitary referral centers who were followed up for a long period and the systematic analysis in terms of tumor progression, providing guidance for clinical practice.
Our study provides systematic data on the previously unknown natural history of regrown CNFAs and on the poorly explored area of clinically aggressive CNFA behavior. It established the importance of continuing followup after therapeutic interventions because these do not offer definitive tumor stability. It also proves the importance of regular, long-term monitoring of regrown CNFAs not offered treatment, as continued progress was seen in a substantial number of patients who ultimately required intervention. The need for intervention should be determined in a multidisciplinary setting and should rely on a risk-benefit balance, with one of the major factors being the prevention of visual morbidity. Given that a prospective study of this scale and duration is unlikely to be feasible, our results aid decision making for all disciplines involved in the management of these patients (endocrinology, oncology, neurosurgery) and highlight the need for enhanced understanding of the biological behavior of these tumors.
